PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of josteoJournal of Osteoporosis
 
J Osteoporos. 2017; 2017: 4982312.
Published online 2017 July 12. doi:  10.1155/2017/4982312
PMCID: PMC5529652

Corrigendum to “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy”

In the article titled “Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy” [1], there was an error regarding the FRAX® tool, which should be clarified as follows.

The article notes, “Fracture Risk Assessment (FRAX) is an algorithm developed by the World Health Organization to determine fracture risk of men and women [8].” However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.

References

1. Neubecker K., Adams-Huet B., Farukhi I. M., Delapena R. C., Gruntmanis U. Predictors of fracture risk and bone mineral density in men with prostate cancer on androgen deprivation therapy. Journal of Osteoporosis. 2011;2011:6. doi: 10.4061/2011/924595.924595 [PMC free article] [PubMed] [Cross Ref]
2. Ford N., Norris S. L., Hill S. R. Clarifying WHO’s position on the FRAX® tool for fracture prediction. Bulletin of the World Health Organization. 2016;94(862) doi: 10.2471/BLT.16.188532. [PMC free article] [PubMed] [Cross Ref]

Articles from Journal of Osteoporosis are provided here courtesy of Hindawi